Skip to main content

About your Search

20130124
20130201
Search Results 0 to 4 of about 5 (some duplicates have been removed)
it. obama has also said investing as a synonym for spending. investing has to be investing. >> if we can't get behind a no-brainer like this, a public/private infrastructure bank, we have a real problem. this is leveraging, private capit capital, should be a no-brainer and it's ridiculous that it's continue tended where the rubber meets the road. >> a no-brainer no matter what side you're on. christy thanks you so much. margaret and john, stop playing footsie. one man, two skis, multiple falls. richard quest is fresh off the bunny slope. ♪ my friends are al ♪ my friends, they do surround me ♪ ♪ i hope this never ends ♪ and we'll be the best of friends ♪ ♪ all set? all set. [ male announcer ] introducing the reimagined 2013 chevrolet traverse, with spacious seating for up to eight. imagine that. >>> all right. richard quest joins me now. he is the host of "quest means business" on cnn international. a perennial all-star in davos. richard, give our viewers a look at what this place, davos, and the world economic forum is really like. where in world are we? davos is europe
battles between president obama and republicans are mostly budget focused. on march 1 one month from this friday sequester cuts kick in. it is $1.2 trillion. those are cuts to military and discretionary spending. paul ryan says don't expect a last minute deal or any deal at all. >> i think the sequester is going to happen because that $1.2 trillion in spending cuts we can't lose those. >> joining me now lynn sweet and david who covers the white house for the washington post. good sunday to both of you. let's start with the claim from paul ryan. $1.2 trillion in cuts said to take effect march 1. paul ryan indicating this time there will be no 11th hour deal. >> it is just a bargain position and it is not going to necessarily unfold that way. there are no absolute right now. it is early in yet another chapter of the on going rangles we have been having. so i would put no more into it. it is a prediction and i don't think either side has anything to gain. remember the virginia economy, a lot of places very dependent on defense and other industries, neither side will look good if they ca
of the technology -- a lot of the advances have come from that. so you want to get reimbursed for spending a lot of money to develop them. but then again, we all have this problem with keeping health care costs down and obama care wants generic competition for biologics. what's the right road to take there? >> you know, joe, we've been in this industry for over 135 years. for us, we've taken a focus and we pursue both small molecule as well as bioological routes to address some of the most oppressing diseases out there. if you take alzheimer's, we have the biologic but we have a base inhibitor in phase two -- >> would you pay a lobbyist, would you get lobbyists for eli lilly to try to make it that you don't have to have generic competition for biologics, is that something eli lilly would do, or do you go along with it? >> well, remember, in the affordable care act we did get an extension in terms of data protection, as we should be, to at least 12 years. we believe that's very important for us to have a reasonable period to generate return on investment that we make in r&d. we still are the indu
Search Results 0 to 4 of about 5 (some duplicates have been removed)